Literature DB >> 20626334

Recent patents and trends in orally disintegrating tablets.

Farhan A AlHusban1, Amr M El-Shaer, Rhys J Jones, Afzal R Mohammed.   

Abstract

Orally disintegrating tablets (ODTs) offer many advantages over the conventional oral dosage forms in terms of convenience and ease of use. Over the last decade, substantial advances in the formulation of ODTs have been achieved in academia and industry that resulted in the emerging of a large number of patents. The aim of this review is to summarise the most recent patents in ODT formulations and highlight their motivations, inventive steps and significances in the development of ODT formulations. Five major techniques have been applied in manufacturing of ODTs, namely conventional tablet press, moulding, freeze drying, tablet loading and pulverization, with majority of the patents dedicated to the use of conventional tablet pressing. The patents have addressed various issues concerning the manufacturing of robust and practical ODT formulations by disclosing new manufacturing techniques, advantageous materials, and innovative formulation steps. However, future developments are required to reduce the cost and widening the application of the new manufacturing techniques, while simplifying and shortening the formulation steps will be crucial in the well established ones.

Mesh:

Substances:

Year:  2010        PMID: 20626334     DOI: 10.2174/187221110793237574

Source DB:  PubMed          Journal:  Recent Pat Drug Deliv Formul        ISSN: 1872-2113


  2 in total

1.  Development of film dosage form containing allopurinol for prevention and treatment of oral mucositis.

Authors:  Yoshifumi Murata; Kyoko Kofuji; Norihisa Nishida; Ryosei Kamaguchi
Journal:  ISRN Pharm       Date:  2012-03-15

2.  A Holistic Multi Evidence Approach to Study the Fragmentation Behaviour of Crystalline Mannitol.

Authors:  Jasdip S Koner; Ali Rajabi-Siahboomi; James Bowen; Yvonne Perrie; Daniel Kirby; Afzal R Mohammed
Journal:  Sci Rep       Date:  2015-11-10       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.